Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Pulmonary hypertension in idiopathic pulmonary fibrosis (IPF) is indicative of a poor prognosis. Recent evidence suggests that tetrahydrobiopterin (BH4), the cofactor of nitric oxide synthase (NOS), is involved in pulmonary hypertension and that pulmonary artery endothelial-to-mesenchymal transition (EnMT) may contribute to pulmonary fibrosis. However, the role of BH4 in pulmonary remodelling secondary to pulmonary fibrosis is unknown. This study examined the BH4 system in plasma and pulmonary arteries from patients with IPF as well as the antiremodelling and antifibrotic effects of the BH4 precursor sepiapterin in rat bleomycin-induced pulmonary fibrosis and in vitro EnMT models. Methods: BH4 and nitrotyrosine were measured by high-performance liquid chromatography and ELISA, respectively. Expression of sepiapterin reductase (SPR), GTP cyclohydrolase 1 (GCH-1), endothelial NOS (eNOS) and inducible NOS (iNOS) were measured by quantitative PCR and immunohistochemistry. Results: BH4 plasma levels were downregulated in patients with IPF compared with controls while nitrites, nitrates and nitrotyrosine were upregulated. GCH-1 and eNOS were absent in pulmonary arteries of patients with IPF; however, iNOS expression increased while SPR expression was unchanged. In rats, oral sepiapterin (10 mg/kg twice daily) attenuated bleomycin-induced pulmonary fibrosis, mortality, vascular remodelling and pulmonary hypertension by increasing rat plasma BH4, decreasing plasma nitrotyrosine and increasing vascular eNOS and GCH-1 expression. Both transforming growth factor β1 and endothelin-1 induced EnMT by decreasing BH4 and eNOS expression. In vitro administration of sepiapterin increased endothelial BH4 and inhibited EnMT in human pulmonary artery endothelial cells. Conclusions: Targeting the BH4 synthesis ‘salvage pathway’ with sepiapterin may be a new therapeutic strategy to attenuate pulmonary hypertension in IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tetrahydrobiopterin: biochemistry and pathophysiology
Werner, E. R., Blau, N., & Thöny, B. (2011) · Biochemical Journal · doi:10.1042/bj20110293 · Cited by 493 · cited 1×
“9 Pulmonary artery expression of eNOS is decreased or absent in the endothelium of patients with IPF while iNOS is highly expressed, in parallel with an increase in reactive oxygen species and nitrotyrosine, in the lung tissue of these patients, which suggests uncoupled NOS activity.”
BackgroundNitric oxide in the pulmonary vasculature
Coggins, M. P., & Bloch, K. D. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.142943 · Cited by 138 · cited 2×
“8 Thus, when BH4 levels are adequate, NOS produces NO; low levels of BH4 cause uncoupled NOS enzymatic activity, generating NO, superoxide and peroxynitrite, thus contributing to vascular oxidative stress and endothelial dysfunction.”
BackgroundSkeletal Muscle Inflammation and Nitric Oxide in Patients with COPD
Montes de Oca, M., Torres, S. H., De Sanctis, J., Mata, A., Hernández, N., & Tálamo, C. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00107404 · Cited by 123
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury
Cortijo, J., Iranzo, A., Milara, X., Mata, M., Cerdá‐Nicolás, M., Ruiz‐Saurí, A., Tenor, H., Hatzelmann, A., & Morcillo, E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00041.x · Cited by 114
Self-citation
Cited by
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Ballester, B., Milara, J., & Cortijo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030593 · Cited by 308
Self-citationThe JAK2 pathway is activated in idiopathic pulmonary fibrosis
Milara, J., Hernandez, G., Ballester, B., Morell, A., Roger, I., Montero, P., Escrivá, J., Lloris, J. M., Molina-Molina, M., Morcillo, E., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0728-9 · Cited by 188
Self-citationInui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
Hayes, D., Black, S. M., Tobias, J. D., Kirkby, S., Mansour, H. M., & Whitson, B. A. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.06.024 · Cited by 66
Metadata
- Authors
- Almudéver, P., Milara, J., De Diego, A., Serrano-Mollar, A., Xaubet, A., Perez-Vizcaino, F., Cogolludo, A., & Cortijo, J.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2013-06-05
- Volume
- 68
- Issue
- 10
- Pages
- 938-948
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2071344942
- Cited by
- 60
- References
- 4
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis. https://app.cochat.ai/papers/10.1136/thoraxjnl-2013-203408
- The paper
- Almudéver, P., Milara, J., De Diego, A., Serrano-Mollar, A., Xaubet, A., Perez-Vizcaino, F., Cogolludo, A., & Cortijo, J. (2013). Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis. Thorax. https://doi.org/10.1136/thoraxjnl-2013-203408
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.